Two doses of Pfizer-BioNTech Covid-19 vaccine greatly reduced the risk of Omicron infection among children aged five to 15, according to a study published by the US Centers for Disease Control and Prevention (CDC).
Children and adolescents aged five to 15 were tested for SARS-CoV-2 weekly, irrespective of symptoms, during July 2021 to February 2022, Xinhua news agency quoted the CDC as saying.
Approximately one half of Omicron infections in unvaccinated children and adolescents were asymptomatic, according to the CDC.
Two doses of Pfizer-BioNTech Covid-19 vaccine reduced the risk of Omicron infection by 31 per cent among children aged five to 11, and by 59 per cent among adolescents aged 12 to 15, according to the CDC study.
The Pfizer-BioNTech mRNA Covid-19 vaccine was recommended by CDC's Advisory Committee on Immunization Practices for adolescents aged 12 to 15 on May 12 last year, and for children aged five to 11 years on November 2, 2021.
--IANS
ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)